A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women.

BACKGROUND AND OBJECTIVE: Although there are a multitude of therapeutic modalities for removing unwanted facial hair in women, there is very little information on using the newer medical treatment approaches in combination. This study was designed to determine whether topical eflornithine can enhance the efficacy of laser hair removal. DESIGN: This was a randomized, double-blind, placebo-controlled, right-left comparison study of eflornithine cream combined with laser treatment versus laser alone for treating unwanted hair on the upper lip in women. All subjects underwent treatment to the entire upper lip with a long pulse alexandrite laser (10-40 ms pulse duration) at fluences of 7 to 40 J/cm(2). Laser treatments were performed every 4 weeks for up to 6 sessions. Each patient also applied either eflornithine or placebo cream twice daily to each side of the upper lip in a double-blinded manner. Subjects were evaluated for safety by recording adverse events and for efficacy via (1) investigator global scoring, (2) patient self assessment, and (3) hair count analysis. RESULTS: Both treatment modalities were well tolerated by the 31 evaluable patients. All 3 outcome measures showed significantly better results in favor of eflornithine plus laser versus laser treatment alone. At the end of the study, complete or almost complete hair removal was achieved in 29 of 31 (93.5%) of the eflornithine-laser-treated sites versus 21 of 31 (67.9%) for the placebo cream-laser-treated sites (P = .021, McNemar test). Statistically significant differences in favor of eflornithine were likewise demonstrated at the final assessment through blinded patient grading (13/31 patients [41.9%] thought that the eflornithine was superior to placebo, P = .029, Poisson regression) and hair count analysis (P < .01, paired t test). LIMITATIONS: This is a single-center study that did not determine whether the differences noted above last beyond 6 months. CONCLUSIONS: On the basis of both investigator and patient assessments and hair count analysis, we have demonstrated that the addition of eflornithine to laser hair removal results in a more rapid and complete reduction of unwanted facial hair in women when the combination is used for up to 6 months.

Long pulsed dye laser treatment of facial wrinkles.

BACKGROUND: The flashlamp pulsed dye laser has been used in the treatment of rhytids. OBJECTIVE: To evaluate the efficacy of the long pulsed dye laser in the treatment of mild to moderate wrinkles in Asian patients. METHODS: Wrinkles on one half of the face in 10 subjects were treated with the long pulsed dye laser (595 nm, 10 mm spot size, 10 ms, 7 J/cm2, 40 ms spray, 40 ms delay, single-pass, 30% overlap) with the other side serving as a control. A total of three treatments were given at 2 monthly intervals. The following sites were treated: periorbital area, six patients; forehead, two patients; cheek, two patients. No preoperative anesthesia or postoperative treatment were used. Clinical photographs were taken before and after each treatment, and analysis was undertaken through photographic evaluation by non-treating physicians. RESULTS: At 2 months after the last treatment, the clinical improvement of rhytids was noted in all patients compared with baseline. Four subjects had mild improvement (< or = 25%), five had moderate improvement (26-50%) and one had marked improvement (51-75%). The periorbital area was more responsive to treatment compared with the other sites. No clinical changes were noted in the control areas. No adverse effects were reported except for transient mild erythema in two patients which lasted for up to an hour. Nine patients were somewhat satisfied with the treatment and one was highly satisfied. All wanted the other half of the face to be treated. CONCLUSION: Treatment with a non-ablative 595 nm flashlamp pulsed dye laser can lead to mild to moderate clinical improvement in class I-II rhytids with minimal to no side effects in patients with darker skin types.